Quick Listen: Scrip’s Five Must-Know Things
Coronavirus, Other Infectious Diseases In Focus
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering the business week ended 17 July.
This week, there are calls for a renewed focus on and investment in infectious diseases in general, as coronavirus vaccine and drug developments continue to attract substantial attention.
Stories mentioned in this episode:
(Also see "Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses" - Scrip, 14 Jul, 2020.)
(Also see "Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism" - Scrip, 10 Jul, 2020.)
(Also see "Novartis Unveils Zero Profit COVID-19 Drugs Portfolio" - Scrip, 16 Jul, 2020.)
(Also see "Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix" - Scrip, 9 Jul, 2020.)
(Also see "Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base" - Scrip, 15 Jul, 2020.)